Melinta Therapeutics

Melinta Therapeutics, Inc. is a commercial-stage pharmaceutical company based in Morristown, New Jersey, specializing in the discovery, development, and commercialization of antibiotics aimed at treating bacterial infections. The company offers several products, including Baxdela, Vabomere, Orbactiv, and Minocin, which target acute bacterial skin infections and gram-negative pathogens. Melinta's mission is to address the urgent need for effective antibiotics to combat drug-resistant infections, a significant public health challenge. The company is actively advancing its late-stage investigational antibiotic, delafloxacin, currently in Phase 3 development for acute bacterial skin and skin structure infections. Additionally, Melinta is engaged in research aimed at developing new antibiotics to tackle resistant pathogens associated with serious hospital-acquired infections. Melinta Therapeutics maintains license agreements with several institutions, including Yale University and Wakunaga Pharmaceutical Co., Ltd., and is supported by investors such as Vatera Healthcare Partners and Warburg Pincus.

Kevin Conway

Vice President, Program Management and Technical Operations

Dan Wechsler

President and CEO

2 past transactions

Tetraphase Pharmaceuticals

Acquisition in 2020
Capitalizing on breakthrough synthetic chemistry, Tetraphase Pharmaceuticals is leveraging a dynamic drug engine targeted at several significant disease categories.

The Medicines Company - Infectious Disease Care

Acquisition in 2017
The Medicines Company - Infectious Disease Care.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.